Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

NCT01953913 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

542

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Afatinib

Sponsor

Boehringer Ingelheim